Overview
Dr. Crosby received her PhD in Immunology from the University of Pennsylvania where she used models of chronic infection to understand how the immune system causes damage to healthy tissue. She arrived at Duke for a postdoctoral fellowship where she applied this knowledge to test new therapies that bypass this immune system regulation to treat breast cancer. Dr. Crosby remained at Duke to start her own research program in 2021.
Current Appointments & Affiliations
Assistant Professor in Surgery
·
2021 - Present
Surgery, Surgical Sciences,
Surgery
Assistant Professor in Molecular Genetics and Microbiology
·
2023 - Present
Molecular Genetics and Microbiology,
Basic Science Departments
Assistant Professor in Integrative Immunobiology
·
2024 - Present
Integrative Immunobiology,
Basic Science Departments
Member of the Duke Cancer Institute
·
2023 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Phase Ib/II study of Pembrolizumab with Lanreotide depot for advanced, progressive Gastroenteropancreatic neuroendocrine tumors (PLANET).
Journal Article J Neuroendocrinol · February 11, 2025 While performing a study of immune checkpoint blockade with the anti-PD-1 antibody pembrolizumab combined with the somatostatin analogue (SSA) lanreotide in patients with low- and intermediate-grade gastroenteropancreatic neuroendocrine tumors (GEP-NETs), ... Full text Link to item CiteVaccines targeting ESR1 activating mutations elicit anti-tumor immune responses and suppress estrogen signaling in therapy resistant ER+ breast cancer.
Journal Article Hum Vaccin Immunother · December 31, 2024 ER+ breast cancers (BC) are characterized by the elevated expression and signaling of estrogen receptor alpha (ESR1), which renders them sensitive to anti-endocrine therapy. While these therapies are clinically effective, prolonged treatment inevitably res ... Full text Link to item CiteAbstract B052: Single-cell and spatial analysis of the immune landscape unveils a subset of potentially tumor-reactive T cells in patients with localized PDAC
Conference Cancer Research · September 15, 2024 AbstractEven in its localized stages, pancreatic ductal adenocarcinoma (PDAC) is virtually incurable, characterized by early dissemination and disease recurrence. The liver is the most common site of metasta ... Full text CiteRecent Grants
Advanced Immunobiology Traning Program for Surgeons
Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2019 - 2029Targeted vaccination against common resistance genes and neoepitope mutation drivers to treat and prevent endocrine-resistant ER+ Breast Cancer
ResearchCo Investigator · Awarded by Department of Defense · 2024 - 2027Spatial multiomic evaluation of clinical responders with advanced triple negative breast cancer from KEYNOTE-890 to validate a published CXCR3 gene signature
ResearchPrincipal Investigator · Awarded by Department of Defense · 2023 - 2027View All Grants
Education, Training & Certifications
University of Pennsylvania ·
2014
Ph.D.
Bucknell University ·
2009
B.S.